A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Phase 3

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Sponsor:

AbbVie

Code:

NCT06012240

Conditions

Alopecia Areata

Eligibility Criteria

Sex: All

Age: 12 - 63

Healthy Volunteers: Not accepted

Interventions

Upadacitinib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information